Results 41 to 50 of about 12,232 (185)

TRIM31–LOX‐1 Axis: A Novel Therapeutic Frontier in Atherosclerosis

iNew Medicine, EarlyView.
ABSTRACT Atherosclerosis, driven by a vicious cycle of lipid accumulation and chronic inflammation, underlies most cardiovascular diseases. Macrophages exacerbate this process by internalizing oxidized low‐density lipoprotein (oxLDL), forming foam cells, and releasing inflammatory mediators. A recent study published in Circulation identified the TRIM31–
Qian Zhang, Cheng Xue Qin
wiley   +1 more source

Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study

BMC Cancer
Background The causal impact of lipid-lowering drugs on ovarian cancer (OC) and cervical cancer (CC) has received considerable attention, but its causal relationship is still a subject of debate.
Jinshuai Li, Zixian Yang, Tao Wang, Mengqi Li, Xiangjian Wu, Xiaoyan Fu, Chunfeng Yang, Yangpu Li, Ximing Wang, Zhiming Lan, Minfang Li, Sheng Chen   +11 more
doaj   +1 more source

Proteomics‐Based Identification of the Pyroptosis‐Related Biomarker PCSK9 and Its Association With the Pathogenesis of Rheumatoid Arthritis

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Rheumatoid arthritis (RA) is a common autoimmune disease, and early diagnosis is critical for effective treatment. This study aims to identify potential biomarkers related to pyroptosis through serum proteomics analysis, offering new insights for the early diagnosis of RA.
Lei Wang, Hao‐Jie Chen, Ting‐Ting Wu, Xin‐Yi Shen, Ying‐Ying Gao, Yu‐Feng Yin, Tian Ren, Xin Chu, Jing Cao, Tao Cheng, Ming‐Jun Wang   +10 more
wiley   +1 more source

Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors

Tzu Chi Medical Journal
A decrease in the levels of low-density lipoprotein receptors (LDLRs) leads to the accumulation of LDL cholesterol (LDL-C) in the bloodstream, resulting in hypercholesterolemia and atherosclerotic cardiovascular diseases.
Je-Wen Liou, Pei-Yi Chen, Wan-Yun Gao, Jui-Hung Yen   +3 more
doaj   +1 more source

Assessing the safety of lipid-modifying medications among Chinese adolescents: a drug-target Mendelian randomization study

BMC Medicine, 2023
Background With increasing hypercholesterolemia prevalence in East Asian adolescents, pharmacologic interventions (e.g., HMGCR inhibitors (statins) and PCSK9 inhibitors) may have to be considered although their longer-term safety in the general ...
Shan Luo, Hugh Simon Lam, Yap Hang Chan, Clara Sze Man Tang, Baoting He, Man Ki Kwok, Gabriel M. Leung, C Mary Schooling, Shiu Lun Au Yeung   +8 more
doaj   +1 more source

PCSK9 inhibitors – past, present and future [PDF]

Expert Opinion on Drug Metabolism & Toxicology, 2015
Lowering low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular disease (CVD) morbidity and mortality. Statins are the treatment of choice for lowering LDL-C but a considerable number of patients treated with statins are unable to achieve LDL-C target values and many are statin-intolerant.
openaire   +2 more sources

Is there a role for cannabidiol in obesity, metabolic syndrome and binge eating?

British Journal of Pharmacology, EarlyView.
Cannabidiol (CBD) is one of the most abundant phytocannabinoids isolated from the Cannabis sativa plant. CBD is a lipophilic, non‐intoxicating substance that differently from Δ9‐tetrahydrocannabinol (Δ9‐THC) does not present the typical profile of a drug of abuse.
Luca Botticelli, Emanuela Micioni Di Bonaventura, Giacomo Einaudi, Gustavo Provensi, Alessia Costa, Claudio D'Addario, Carlo Cifani, Maria Vittoria Micioni Di Bonaventura   +7 more
wiley   +1 more source

The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis

Frontiers in Cardiovascular Medicine
BackgroundIn recent years, the position of PCSK9 inhibitors as adjuvant therapy to statins in guidelines has further improved. However, there remained a dearth of direct comparative studies among different PCSK9 inhibitors. Therefore, this study aimed to
Dong Liu, Jin Zhang, Xiaoyu Zhang, Fengli Jiang, Yiping Wu, Beibei Yang, Xinghuan Li, Xiongxiong Fan, Han Li, Yu Sun, Ruijie Gou, Xinyu Wang   +11 more
doaj   +1 more source

A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro

Molecules, 2018
The interaction between proprotein convertase subtilisin/kexin type 9 (PCSK9) and the low-density lipoprotein receptor (LDLR) is a promising target for the treatment of hyperc-holesterolemia.
Li Li, Chen Shen, Ya-Xuan Huang, Ya-Nan Li, Xiu-Feng Liu, Xu-Ming Liu, Ji-Hua Liu   +6 more
doaj   +1 more source

PCSK9 peptide inhibitors [PDF]

Science-Business eXchange, 2014
Although many companies are chasing inhibitors of PCSK9 for lowering LDL cholesterol, antibodies or siRNAs that require injection are dominating the field. Roche's Genentech unit and a joint team from Pfizer and the University of Queensland are betting that peptides might provide an oral competitor.
openaire   +1 more source